This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bogaert, D. Articles by Hermans, P. W. M. Search for Related Content PubMed PubMed Citation Articles by Bogaert, D. Articles by Hermans, P. W. M.

 Previous Article  |  Next Article 

Infection and Immunity, February 2004, p. 818-823, Vol. 72, No. 2
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.2.818-823.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Host-Pathogen Interaction during Pneumococcal Infection in Patients with Chronic Obstructive Pulmonary Disease

Department of Pediatrics, Erasmus MC-Sophia, Rotterdam,¹ Department of Pulmonology, Medisch Spectrum Twente,² Regional Laboratory of Public Health, Enschede, The Netherlands³

Received 29 August 2003/ Returned for modification 9 October 2003/ Accepted 12 November 2003

Acute exacerbation is a frequent complication of chronic obstructive pulmonary disease (COPD). Recent studies suggested a role for bacteria such as Streptococcus pneumoniae in the development of acute exacerbation. For this study, we investigated the following in COPD patients: (i) the epidemiology of pneumococcal colonization and infection, (ii) the effect of pneumococcal colonization on the development of exacerbation, and (iii) the immunological response against S. pneumoniae. We cultured sputa of 269 COPD patients during a stable state and during exacerbation of COPD and characterized 115 pneumococcal isolates by use of serotyping. Moreover, we studied serum immunoglobulin G (IgG) antibody titers, antibody avidities, and functional antibody titers against the seven conjugate vaccine serotypes in these patients. Colonization with only pneumococci (monocultures) increased the risk of exacerbation, with a hazard ratio of 2.93 (95% confidence interval, 1.41 to 6.07). The most prevalent pneumococcal serotypes found were serotypes 19F, 3, 14, 9L/N/V, 23A/B, and 11. We calculated the theoretical coverage for the 7- and 11-valent pneumococcal vaccines to be 60 and 73%, respectively. All patients had detectable IgG levels against the seven conjugate vaccine serotypes. These antibody titers were significantly lower than those in vaccinated healthy adults. Finally, on average, a 2.5-fold rise in serotype-specific and functional antibodies in S. pneumoniae-positive sputum cultures was observed during exacerbation. Our data indicate that pneumococcal colonization in COPD patients is frequently caused by vaccine serotype strains. Moreover, pneumococcal colonization is a risk factor for exacerbation of COPD. Finally, our findings demonstrate that COPD patients are able to mount a significant immune response to pneumococcal infection. COPD patients may therefore benefit from pneumococcal vaccination.

Editor: J. N. Weiser

This article has been cited by other articles:

• Abusriwil, H., Stockley, R. A. (2007). The Interaction of Host and Pathogen Factors in Chronic Obstructive Pulmonary Disease Exacerbations and Their Role in Tissue Damage. Proc Am Thorac Soc 4: 611-617 [Abstract] [Full Text]  
• Sykes, A., Mallia, P., Johnston, S. L. (2007). Diagnosis of Pathogens in Exacerbations of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 4: 642-646 [Abstract] [Full Text]  
• Sethi, S., Sethi, R., Eschberger, K., Lobbins, P., Cai, X., Grant, B. J. B., Murphy, T. F. (2007). Airway Bacterial Concentrations and Exacerbations of Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 176: 356-361 [Abstract] [Full Text]  
• Chen, M., Hisatomi, Y., Furumoto, A., Kawakami, K., Masaki, H., Nagatake, T., Sueyasu, Y., Iwanaga, T., Aizawa, H., Oishi, K. (2007). Comparative Immune Responses of Patients with Chronic Pulmonary Diseases during the 2-Year Period after Pneumococcal Vaccination. CVI 14: 139-145 [Abstract] [Full Text]  
• Burge, P. S. (2006). Prevention of Exacerbations: How Are We Doing and Can We Do Better?. Proc Am Thorac Soc 3: 257-261 [Abstract] [Full Text]  
• Sapey, E, Stockley, R A (2006). COPD exacerbations {middle dot} 2: Aetiology.. Thorax 61: 250-258 [Abstract] [Full Text]